Format
Sort by
Items per page

Send to

Choose Destination

Best matches for Rådegran G[au]:

Search results

Items: 1 to 50 of 112

1.

Bone Mineral Density in Relation to Chronic Kidney Disease After Heart Transplantation: A Retrospective Single-center Study at Skåne University Hospital in Lund 1988-2016.

Löfdahl E, Haggård C, Rådegran G.

Transplant Direct. 2020 Feb 24;6(3):e537. doi: 10.1097/TXD.0000000000000981. eCollection 2020 Mar.

2.

Invasive haemodynamics in de novo everolimus vs. calcineurin inhibitor heart transplant recipients.

Bergh N, Gude E, Bartfay SE, K Andreassen A, Arora S, Dahlberg P, Dellgren G, Gullestad L, Gustafsson F, Karasson K, Rådegran G, Bollano E, Andersson B.

ESC Heart Fail. 2020 Feb 14. doi: 10.1002/ehf2.12608. [Epub ahead of print]

3.

Elevated plasma tyrosine kinases VEGF-D and HER4 in heart failure patients decrease after heart transplantation in association with improved haemodynamics.

Ahmed S, Ahmed A, Säleby J, Bouzina H, Lundgren J, Rådegran G.

Heart Vessels. 2020 Jan 20. doi: 10.1007/s00380-019-01548-1. [Epub ahead of print]

PMID:
31960146
4.

Mild acute cellular rejection and development of cardiac allograft vasculopathy assessed by intravascular ultrasound and coronary angiography in heart transplant recipients-a SCHEDULE trial substudy.

Nelson LM, Andreassen AK, Arora S, Andersson B, Gude E, Eiskjaer H, Rådegran G, Dellgren G, Gullestad L, Gustafsson F.

Transpl Int. 2020 Jan 20. doi: 10.1111/tri.13577. [Epub ahead of print]

PMID:
31958178
5.

Higher plasma fibroblast growth factor 23 levels are associated with a higher risk profile in pulmonary arterial hypertension.

Bouzina H, Hesselstrand R, Rådegran G.

Pulm Circ. 2019 Dec 27;9(4):2045894019895446. doi: 10.1177/2045894019895446. eCollection 2019 Oct-Dec.

6.

Matrix metalloproteinase 7 in diagnosis and differentiation of pulmonary arterial hypertension.

Arvidsson M, Ahmed A, Bouzina H, Rådegran G.

Pulm Circ. 2019 Dec 27;9(4):2045894019895414. doi: 10.1177/2045894019895414. eCollection 2019 Oct-Dec.

7.

Increased pulmonary blood volume variation in patients with heart failure compared to healthy controls: a noninvasive, quantitative measure of heart failure.

Al-Mashat M, Jögi J, Carlsson M, Borgquist R, Ostenfeld E, Magnusson M, Bachus E, Rådegran G, Arheden H, Kanski M.

J Appl Physiol (1985). 2020 Feb 1;128(2):324-337. doi: 10.1152/japplphysiol.00507.2019. Epub 2019 Dec 24.

8.

Profiling of the plasma proteome across different stages of human heart failure.

Egerstedt A, Berntsson J, Smith ML, Gidlöf O, Nilsson R, Benson M, Wells QS, Celik S, Lejonberg C, Farrell L, Sinha S, Shen D, Lundgren J, Rådegran G, Ngo D, Engström G, Yang Q, Wang TJ, Gerszten RE, Smith JG.

Nat Commun. 2019 Dec 20;10(1):5830. doi: 10.1038/s41467-019-13306-y.

9.

Prolargin and matrix metalloproteinase-2 in heart failure after heart transplantation and their association with haemodynamics.

Ahmed A, Ahmed S, Arvidsson M, Bouzina H, Lundgren J, Rådegran G.

ESC Heart Fail. 2020 Feb;7(1):223-234. doi: 10.1002/ehf2.12560. Epub 2019 Dec 19.

10.

Plasma receptor tyrosine kinase RET in pulmonary arterial hypertension diagnosis and differentiation.

Säleby J, Bouzina H, Ahmed S, Lundgren J, Rådegran G.

ERJ Open Res. 2019 Nov 15;5(4). pii: 00037-2019. doi: 10.1183/23120541.00037-2019. eCollection 2019 Oct.

11.

Pulmonary arterial hypertension in systemic sclerosis-when criteria and pathobiology differ.

Andréasson K, Rådegran G, Brunnström H, Wuttge DM, Hesselstrand R.

Rheumatology (Oxford). 2019 Oct 14. pii: kez474. doi: 10.1093/rheumatology/kez474. [Epub ahead of print] No abstract available.

PMID:
31608943
12.

Functional Screening Identifies MicroRNA Regulators of Corin Activity and Atrial Natriuretic Peptide Biogenesis.

Celik S, Karbalaei-Sadegh M, Rådegran G, Smith JG, Gidlöf O.

Mol Cell Biol. 2019 Nov 12;39(23). pii: e00271-19. doi: 10.1128/MCB.00271-19. Print 2019 Dec 1.

13.

Sex-specific differences and survival in patients with idiopathic pulmonary arterial hypertension 2008-2016.

Kjellström B, Nisell M, Kylhammar D, Bartfay SE, Ivarsson B, Rådegran G, Hjalmarsson C.

ERJ Open Res. 2019 Aug 12;5(3). pii: 00075-2019. doi: 10.1183/23120541.00075-2019. eCollection 2019 Jul. Erratum in: ERJ Open Res. 2019 Aug 30;5(3):.

14.

[Patients' perspective of living with PAH or CTEPH in Sweden].

Ivarsson B, Hesselstrand R, Rådegran G, Kjellström B.

Lakartidningen. 2019 May 1;116. pii: FITF. Swedish.

15.

[Pulmonary hypertension due to left heart disease - not to be confused with pulmonary arterial hypertension].

Lundgren J, Rådegran G.

Lakartidningen. 2019 Mar 26;116. pii: FI6I. Swedish.

16.

Everolimus Initiation With Early Calcineurin Inhibitor Withdrawal in De Novo Heart Transplant Recipients: Long-term Follow-up From the Randomized SCHEDULE Study.

Gustafsson F, Andreassen AK, Andersson B, Eiskjær H, Rådegran G, Gude E, Jansson K, Solbu D, Karason K, Arora S, Dellgren G, Gullestad L; SCHEDULE (Scandinavian heart transplant everolimus de novo study with early calcineurin inhibitors avoidance) Investigators*.

Transplantation. 2020 Jan;104(1):154-164. doi: 10.1097/TP.0000000000002702.

PMID:
30893292
17.

Everyday life experiences of spouses of patients who suffer from pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension.

Ivarsson B, Sjöberg T, Hesselstrand R, Rådegran G, Kjellström B.

ERJ Open Res. 2019 Feb 25;5(1). pii: 00218-2018. doi: 10.1183/23120541.00218-2018. eCollection 2019 Feb.

18.

Impact of gender on echocardiographic characteristics in heart transplant recipients.

Ingvarsson A, Werther-Evaldsson A, Smith GJ, Waktare J, Nilsson J, Stagmo M, Roijer A, Rådegran G, Meurling C.

Clin Physiol Funct Imaging. 2019 Jul;39(4):246-254. doi: 10.1111/cpf.12565. Epub 2019 Mar 6.

PMID:
30770630
19.

Behandlingen av patienter med svår hjärtsvikt kan förbättras - Eftersatt tillstånd som fortfarande underbehandlas.

Bjurman C, Holzmann M, Juhlin T, Rådegran G.

Lakartidningen. 2018 Dec 28;115. pii: FDX6. Review. Swedish. No abstract available.

20.

Bone mineral density and osteoporosis in heart transplanted patients: A single-center retrospective study at Skåne University Hospital in Lund 1988-2016.

Löfdahl E, Söderlund C, Rådegran G.

Clin Transplant. 2019 Mar;33(3):e13477. doi: 10.1111/ctr.13477. Epub 2019 Jan 30.

PMID:
30618200
21.

Decreased biventricular longitudinal strain in patients with systemic sclerosis is mainly caused by pulmonary hypertension and not by systemic sclerosis per se.

Lindholm A, Hesselstrand R, Rådegran G, Arheden H, Ostenfeld E.

Clin Physiol Funct Imaging. 2019 May;39(3):215-225. doi: 10.1111/cpf.12561. Epub 2019 Jan 16.

22.

Low plasma stem cell factor combined with high transforming growth factor-α identifies high-risk patients in pulmonary arterial hypertension.

Bouzina H, Rådegran G.

ERJ Open Res. 2018 Nov 12;4(4). pii: 00035-2018. doi: 10.1183/23120541.00035-2018. eCollection 2018 Oct.

23.

Pulmonary arterial hypertension: assessing risk to improve prognosis.

Kjellström B, Hjalmarsson C, Kylhammar D, Rådegran G.

Expert Rev Cardiovasc Ther. 2019 Jan;17(1):1-2. doi: 10.1080/14779072.2019.1548278. Epub 2018 Nov 15. No abstract available.

PMID:
30422719
24.

Echocardiographic right ventricular strain from multiple apical views is superior for assessment of right ventricular systolic function.

Werther Evaldsson A, Ingvarsson A, Smith JG, Rådegran G, Roijer A, Waktare J, Ostenfeld E, Meurling C.

Clin Physiol Funct Imaging. 2019 Mar;39(2):168-176. doi: 10.1111/cpf.12552. Epub 2018 Oct 30.

PMID:
30375714
25.

Effect of Everolimus Initiation and Calcineurin Inhibitor Elimination on Cardiac Allograft Vasculopathy in De Novo Heart Transplant Recipients.

Arora S, Andreassen AK, Karason K, Gustafsson F, Eiskjær H, Bøtker HE, Rådegran G, Gude E, Ioanes D, Solbu D, Dellgren G, Ueland T, Aukrust P, Gullestad L; SCHEDULE (Scandinavian Heart Transplant Everolimus De Novo Study With Early Calcineurin Inhibitors Avoidance) Investigators.

Circ Heart Fail. 2018 Sep;11(9):e004050. doi: 10.1161/CIRCHEARTFAILURE.117.004050.

PMID:
30354362
26.
27.

Diagnosing and grading heart failure with tomographic perfusion lung scintigraphy: validation with right heart catheterization.

Jögi J, Al-Mashat M, Rådegran G, Bajc M, Arheden H.

ESC Heart Fail. 2018 Oct;5(5):902-910. doi: 10.1002/ehf2.12317. Epub 2018 Jul 17.

28.

Health-related quality of life, treatment adherence and psychosocial support in patients with pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension.

Ivarsson B, Hesselstrand R, Rådegran G, Kjellström B.

Chron Respir Dis. 2019 Jan-Dec;16:1479972318787906. doi: 10.1177/1479972318787906. Epub 2018 Jul 16.

29.

Increased right atrial volume measured with cardiac magnetic resonance is associated with worse clinical outcome in patients with pre-capillary pulmonary hypertension.

Bredfelt A, Rådegran G, Hesselstrand R, Arheden H, Ostenfeld E.

ESC Heart Fail. 2018 Oct;5(5):864-875. doi: 10.1002/ehf2.12304. Epub 2018 Jun 19.

30.

[50 years of heart transplantations].

Söderlund C, Rådegran G.

Lakartidningen. 2018 Apr 12;115. pii: E4ZH. Swedish.

31.

Alterations in plasma L-arginine and methylarginines in heart failure and after heart transplantation.

Lundgren J, Sandqvist A, Hedeland M, Bondesson U, Wikström G, Rådegran G.

Scand Cardiovasc J. 2018 Aug;52(4):196-204. doi: 10.1080/14017431.2018.1459823. Epub 2018 Apr 12.

PMID:
29648475
32.

Impact of age and comorbidity on risk stratification in idiopathic pulmonary arterial hypertension.

Hjalmarsson C, Rådegran G, Kylhammar D, Rundqvist B, Multing J, Nisell MD, Kjellström B; SveFPH and SPAHR.

Eur Respir J. 2018 May 3;51(5). pii: 1702310. doi: 10.1183/13993003.02310-2017. Print 2018 May.

33.

Angiogenic and inflammatory biomarkers for screening and follow-up in patients with pulmonary arterial hypertension.

Kylhammar D, Hesselstrand R, Nielsen S, Scheele C, Rådegran G.

Scand J Rheumatol. 2018 Jul;47(4):319-324. doi: 10.1080/03009742.2017.1378714. Epub 2018 Mar 12.

PMID:
29528272
34.

Adherence and medication belief in patients with pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension: A nationwide population-based cohort survey.

Ivarsson B, Hesselstrand R, Rådegran G, Kjellström B.

Clin Respir J. 2018 Jun;12(6):2029-2035. doi: 10.1111/crj.12770. Epub 2018 Feb 5.

PMID:
29356440
35.

Coping, social support and information in patients with pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension: A 2-year retrospective cohort study.

Ivarsson B, Rådegran G, Hesselstrand R, Kjellström B.

SAGE Open Med. 2018 Jan 4;6:2050312117749159. doi: 10.1177/2050312117749159. eCollection 2018.

36.

[Pulmonary hypertension – a common condition in left heart disease].

Lundgren J, Rådegran G.

Lakartidningen. 2017 Dec 1;114. pii: ER3E. Review. Swedish.

37.

Normal Reference Ranges for Transthoracic Echocardiography Following Heart Transplantation.

Ingvarsson A, Werther Evaldsson A, Waktare J, Nilsson J, Smith GJ, Stagmo M, Roijer A, Rådegran G, Meurling CJ.

J Am Soc Echocardiogr. 2018 Mar;31(3):349-360. doi: 10.1016/j.echo.2017.11.003. Epub 2017 Dec 21.

PMID:
29275986
38.

Right ventricular speckle tracking assessment for differentiation of pressure- versus volume-overloaded right ventricle.

Werther Evaldsson A, Ingvarsson A, Waktare J, Smith GJ, Thilén U, Stagmo M, Roijer A, Rådegran G, Meurling C.

Clin Physiol Funct Imaging. 2018 Sep;38(5):763-771. doi: 10.1111/cpf.12477. Epub 2017 Oct 26.

PMID:
29076284
39.

Plasma L-arginine levels distinguish pulmonary arterial hypertension from left ventricular systolic dysfunction.

Sandqvist A, Schneede J, Kylhammar D, Henrohn D, Lundgren J, Hedeland M, Bondesson U, Rådegran G, Wikström G.

Heart Vessels. 2018 Mar;33(3):255-263. doi: 10.1007/s00380-017-1055-7. Epub 2017 Oct 3.

40.

Osteoporosis following heart transplantation and immunosuppressive therapy.

Löfdahl E, Rådegran G.

Transplant Rev (Orlando). 2017 Oct;31(4):232-239. doi: 10.1016/j.trre.2017.08.002. Epub 2017 Aug 12. Review.

PMID:
28865930
41.

Angiogenic and inflammatory biomarkers in the differentiation of pulmonary hypertension.

Säleby J, Bouzina H, Lundgren J, Rådegran G.

Scand Cardiovasc J. 2017 Oct;51(5):261-270. doi: 10.1080/14017431.2017.1359419. Epub 2017 Aug 4.

PMID:
28776404
42.

[Pulmonary hypertension due to lung diseases].

Kylhammar D, Rådegran G.

Lakartidningen. 2017 Jul 21;114. pii: ELAL. Review. Swedish.

43.

Effect of everolimus vs calcineurin inhibitors on quality of life in heart transplant recipients during a 3-year follow-up: Results of a randomized controlled trial (SCHEDULE).

Relbo Authen A, Grov I, Karason K, Gustafsson F, Eiskjaer H, Rådegran G, Gude E, Jansson K, Dellgren G, Solbu D, Arora S, Andreassen AK, Gullestad L.

Clin Transplant. 2017 Sep;31(9). doi: 10.1111/ctr.13038. Epub 2017 Jul 19.

PMID:
28640529
44.

A comprehensive risk stratification at early follow-up determines prognosis in pulmonary arterial hypertension.

Kylhammar D, Kjellström B, Hjalmarsson C, Jansson K, Nisell M, Söderberg S, Wikström G, Rådegran G.

Eur Heart J. 2018 Dec 14;39(47):4175-4181. doi: 10.1093/eurheartj/ehx257.

PMID:
28575277
45.

Acute cellular rejection later than one year after heart transplantation: A single-center retrospective study at Skåne University Hospital in Lund 1988-2010.

Söderlund C, Rådegran G.

Clin Transplant. 2017 Jul;31(7). doi: 10.1111/ctr.12998. Epub 2017 May 29.

PMID:
28480572
46.

Impact of postoperative pulmonary hypertension on outcome after heart transplantation.

Lundgren J, Söderlund C, Rådegran G.

Scand Cardiovasc J. 2017 Jun;51(3):172-181. doi: 10.1080/14017431.2017.1304569. Epub 2017 Mar 22.

PMID:
28326855
47.

Effect of Calcineurin Inhibitor-Free, Everolimus-Based Immunosuppressive Regimen on Albuminuria and Glomerular Filtration Rate After Heart Transplantation.

Nelson LM, Andreassen AK, Andersson B, Gude E, Eiskjær H, Rådegran G, Dellgren G, Gullestad L, Gustafsson F.

Transplantation. 2017 Nov;101(11):2793-2800. doi: 10.1097/TP.0000000000001706.

PMID:
28230646
48.

Information, social support and coping in patients with pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension-A nationwide population-based study.

Ivarsson B, Rådegran G, Hesselstrand R, Kjellström B.

Patient Educ Couns. 2017 May;100(5):936-942. doi: 10.1016/j.pec.2016.12.021. Epub 2016 Dec 21.

PMID:
28041647
49.

Discriminatory ability of right atrial volumes with two- and three-dimensional echocardiography to detect elevated right atrial pressure in pulmonary hypertension.

Ostenfeld E, Werther-Evaldsson A, Engblom H, Ingvarsson A, Roijer A, Meurling C, Holm J, Rådegran G, Carlsson M.

Clin Physiol Funct Imaging. 2018 Mar;38(2):192-199. doi: 10.1111/cpf.12398. Epub 2016 Dec 7.

PMID:
27925364
50.

The principal pathways involved in the in vivo modulation of hypoxic pulmonary vasoconstriction, pulmonary arterial remodelling and pulmonary hypertension.

Kylhammar D, Rådegran G.

Acta Physiol (Oxf). 2017 Apr;219(4):728-756. doi: 10.1111/apha.12749. Epub 2016 Jul 31. Review.

PMID:
27381367

Supplemental Content

Loading ...
Support Center